Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.49 |
| ▸ | INMT | O95050 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA4 | P22748 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA7 | P43166 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3858131 | 1.00 | LMNA (0.49) | LMNAINMTKMT2ACA12CA1 | |
| SCHEMBL4084509 | 1.00 | LMNA (0.49) | LMNAINMTKMT2ACA12CA1 | |
| SCHEMBL3826928 | 0.87 | LMNA (0.46) | LMNAINMTKMT2ACA12CA1 | |
| SCHEMBL14644848 | 0.83 | LMNA (0.45) | LMNAKMT2ACA12CA1CA2 | |
| SCHEMBL3378778 | 0.82 | LMNA (0.50) | LMNAINMTKMT2ACA12CA1 | |
| SCHEMBL3378768 | 0.82 | LMNA (0.50) | LMNAINMTKMT2ACA12CA1 | |
| SCHEMBL3378771 | 0.82 | LMNA (0.50) | LMNAINMTKMT2ACA12CA1 | |
| SCHEMBL4607217 | 0.81 | LMNA (0.46) | LMNAINMTKMT2ABLMKDM4E | |
| SCHEMBL1737650 | 0.77 | LMNA (0.48) | LMNAINMTKMT2ACA12CA1 | |
| SCHEMBL1737652 | 0.77 | LMNA (0.48) | LMNAINMTKMT2ACA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1587620-B1 | HYDROGENATION CATALYSTS | UCB PHARMA SA (BE) | 2009-09-09 | — | — | EP | claimed |
| EP-1587620-A1 | HYDROGENATION CATALYSTS | UCB, S.A. (BE) | 2005-10-26 | — | — | EP | claimed |
| WO-2004062797-A1 | HYDROGENATION CATALYSTS | UCB, S.A. (BE) | 2004-07-29 | — | — | WO | claimed |
| EP-1587620-B1 | HYDROGENATION CATALYSTS | UCB PHARMA SA (BE) | 2009-09-09 | — | — | EP | disclosed |
| US-20060224001-A1 | Asymmetric hydrogenation of methyl (Z,E)-2-(2oxotetrahydro-1H-1-pyrrolyl)-2-butenoate with [Rh-(S,S-MeDUPHOS)(COD)BF4 ] immobilised on BETA zeolite; high activity; easy recovery and reuse, which is ecologically and economically advantageous | UCB, S.A. (BE) | 2006-10-05 | — | — | US | disclosed |
| EP-1587620-A1 | HYDROGENATION CATALYSTS | UCB, S.A. (BE) | 2005-10-26 | — | — | EP | disclosed |
| WO-2004062797-A1 | HYDROGENATION CATALYSTS | UCB, S.A. (BE) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060224001-A1 | Asymmetric hydrogenation of methyl (Z,E)-2-(2oxotetrahydro-1H-1-pyrrolyl)-2-butenoate with [Rh-(S,S-MeDUPHOS)(COD)BF4 ] immobilised on BETA zeolite; high activity; easy recovery and reuse, which is ecologically and economically advantageous | DBH, HRH4, HMBS | LMNA 4459/4885INMT 1057/4885KMT2A 1581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.